Bausch & Lomb Corp

BLCO

Company Profile

  • Business description

    Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

  • Contact

    520 Applewood Crescent
    VaughanONL4K 4B4
    CAN

    T: +1 905 695-7700

    https://www.bausch.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Instruments & Supplies

    Fiscal Year End

    31 December 2026

    Employees

    13,500

Stocks News & Analysis

stocks

Undervalued by 17%, this US cybersecurity leader is a buy for 2026

Here’s a wide-moat company with strong secular tailwinds in a promising industry—and an attractive stock price, too.
stocks

Tough conditions for ASX listed wagering leader

Wagering continues to be challenged in Australia.
stocks

Chart of the Week: Inflation fears dampen sentiment on retailers

Rising inflation is the fly in the ointment.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,045.9027.80-0.31%
CAC 408,292.4649.000.59%
DAX 4025,145.0917.630.07%
Dow JONES (US)49,266.11270.030.55%
FTSE 10010,084.2239.530.39%
HKSE26,231.7982.480.32%
NASDAQ23,480.02104.26-0.44%
Nikkei 22551,939.89822.631.61%
NZX 50 Index13,696.2520.61-0.15%
S&P 5006,921.460.530.01%
S&P/ASX 2008,717.8029.10-0.33%
SSE Composite Index4,120.4337.450.92%

Market Movers